Effectivity of Daptomycin therapy in patients with febrile neutropenia

摘要

Background: Daptomycin (DAP) has the most potent in vitro and bactericidal activity against Gram-positive (G+) pathogens in comparison to other anti-MRSA agents (vancomycin teicoplanin, linezolid and tigecycline). Clinical data for DAP in the treatment of neutropenic patients are limited. The aim of this study was to evaluate the efficacy of DAP in febrile neutropenic patients.